Literature DB >> 627406

Binding of activated properdin to untreated erythrocytes: a new function of activated properdin.

T Konno, H Hirai, N Tamura.   

Abstract

Activated human properdin was found to be capable of binding to rabbit and sheep erythrocytes to form new intermediate cells of the alternative pathway of the complement system. The intermediate cells, termed EP, can react with B, D and C3 to form other intermediate cells, tentatively termed EPB(D)C3, which can be lysed by the subsequent action of six late-acting complement components, C3 to C9. The possibility of participation of C3, B, D or immunoglobulin in the formation of EP cells was neglected by the experiments in which the inhibition of the reactivities of P or EP by antisera to P, C3, B, D or immunoglobulins were investigated. The reduction in reactivities of P to E, or of EP to B, D and C3 was observed only when pretreated with antiserum to P. Furthermore, EP cells were agglutinated only by anti-P, not by antisera to C3 or IgG. The other possibility of participation of the classical complement components such as antibody, C1, C4 and C2 in the formation of EPB(D)C3 was excluded by the non-reactivities of EP with C4 and C2 and of EAC1 with B, D and C3. Thus, activated properdin is likely to function not only as modulator of preformed enzyme such as C3bBb but also as one of early-acting components of the alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 627406      PMCID: PMC1457703     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  MOUSE BETA-1C-GLOBULIN: PRODUCTION OF ANTISERUM AND CHARACTERIZATION IN THE COMPLEMENT REACTION.

Authors:  M R MARDINEY; H J MUELLER-EBERHARD
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Activation of the alternate pathway of human complements by rabbit cells.

Authors:  T A Platts-Mills; K Ishizaka
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

4.  The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.

Authors:  A E Stitzel; R E Spitzer
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

5.  An improved method for separation of the fourth component of complement and C4 inactivating substance.

Authors:  K Shimada; M Mayumi; T Sekine; K Nishioka
Journal:  Jpn J Exp Med       Date:  1972-10

6.  A molecular concept of the properdin pathway.

Authors:  R G Medicus; R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

7.  Enharncement of the hemolytic activity of the second component of human complement by oxidation.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

8.  Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.

Authors:  D T Fearon; K F Austen; S Ruddy
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

9.  Properdin factor D. II. Activation to D by properdin.

Authors:  D T Fearon; K F Austen; S Ruddy
Journal:  J Exp Med       Date:  1974-08-01       Impact factor: 14.307

10.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.